Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies-Reference-Cited by-同舟云学术

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies

Published:2018-11 Issue:6 Volume:32 Page:499-507
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Teh Benjamin W.,Tam Constantine S.,Handunnetti Sasanka,Worth Leon J.,Slavin Monica A.

Funder

Peter MacCallum Cancer Centre

National Health and Medical Research Council

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference80 articles.

1. Management of infectious complications in patients with chronic lymphocytic leukemia;Morrison;Hematology Am Soc Hematol Educ Program,2007

2. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis;Morrison;Clin Lymphoma Myeloma,2009

3. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes;Molteni;Haematologica,2005

4. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia;Hensel;Br J Haematol,2003

5. Chronic lymphocytic leukemia in the elderly: epidemiology and proposed patient-related approach;Balducci;Cancer Control,2015

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors;Critical Reviews in Oncology/Hematology;2024-09

2. IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence;Blood Advances;2024-08-14

3. How to treat a patient with psoriatic arthritis and chronic lymphocytic leukemia?;Exploration of Musculoskeletal Diseases;2024-06-20

4. Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia;International Journal of Molecular Sciences;2024-06-07

5. Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024);CHINESE J CANCER RES;2024